Stockreport

Immunomedics Provides Corporate Update

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunothe [Read more]